Your PDF document is being created.


Loading



NEW TESTS
Please Note: Not all test codes assigned to each assay are listed in the table of contents.
Please refer to the complete listing on the page numbers indicated.
Test Code Test Name Effective Date Page #
14258 AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma 3/3/2025
13694 NPM1 Mutation for MRD, Quantitative PCR 3/3/2025
13817 Plasma Renin Activity with Reflex to Aldosterone 3/17/2025

Note: It may be 24 - 48 hours after the published effective date before this test information is available on the Online Test Directory or in Quanum™.

Announcements

AD-Detect™ ABeta 42/40 and p-tau217 Evaluation

Quest Diagnostics is pleased to introduce the most recent expansion of our Brain Health portfolio with the release of AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma. This profile contains both plasma beta-amyloid 42/40 ratio and p-tau217. In a Quest-run validation study, these biomarkers combined show an enhanced accuracy of over 90% sensitivity and specificity to meet the CEOi recommendations. Independent measurement and interpretation of plasma amyloid ratios (AB42/40) and phosphorylated tau levels (p-tau181 and p-tau217) provide clinically valuable insight into patient risk for development of Alzheimer’s disease. Combining these core AD pathological markers for a single analytical interpretation has been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity and confirming a diagnosis of Alzheimer’s disease. Improving patient outcomes and care pathways drives Quest Diagnostics’ continued expansion of accessible AD and dementia assessments within our blood-based offerings. Visit QuestForTheCure.com to see how we are continuing to transform cognitive health assessment and diagnostics.

NPM1 Mutation, Quantitative, PCR

Quest Diagnostics is pleased to announce the launch of NPM1 Mutation, Quantitative PCR, an allele specific qPio.CR assay that is used in post-remission MRD monitoring of patients diagnosed with Acute Myeloid Leukemia (AML). MRD monitoring is essential in guiding post-remission therapy and identifying potential early relapse in AML patient management, therefore this is a critical and timely addition to the Quest Oncology Portfolio.

Plasma Renin Activity

Quest Diagnostics is pleased to announce the launch of the Plasma Renin Activity (PRA) Reflex to Aldosterone, LC-MS/MS test. Primary Aldosteronism (PA) is underrecognized and the most common cause of secondary hypertension. Patients with untreated PA are at a disproportionately higher risk of cardiovascular, kidney and metabolic disease when compared to essential hypertensive patients.

 

New Test Offerings

The following tests will be available through Quest Diagnostics on the dates indicated below.

AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma
Clinical Significance Intended use is for Alzheimer's Diagnosis. Independent measurement and interpretation of plasma amyloid ratios (AB42/40) and phosphorylated tau levels (p-tau181 and p-tau217) provide clinically valuable insight into patient risk for development of Alzheimer’s disease. However, by combining core AD pathological markers for a single analytical interpretation have been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity and confirming a diagnosis of Alzheimer’s disease. The AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma evaluates a patient’s plasma AB42/40 ratios and p-tau217 levels reporting out the likelihood that a symptomatic patient suspected of AD has a High, Indeterminant, or Low likelihood of amyloid pathology consistent with AD. This panel meets established performance criteria for confirming a diagnosis of Alzheimer’s disease utilizing plasma biomarkers.
Effective Date 3/3/2025
Test Code 14258
CPT Codes 82233, 82234, 84393
Specimen Requirements 2 mL (1.1 mL minimum) plasma collected in a K2 EDTA (lavender-top) tube
Reject Criteria Moderate or gross hemolysis; specimen collected in a glass, polystyrene, or polycarbonate tube
Instructions Patient Preparation:
Patients should be cautioned to stop biotin consumption at least 72 hours prior to collection of a sample
 
Instructions: 
Quest Diagnostics does not perform this test for individuals under the age of 18. Pre-test and post-test counseling is strongly recommended.
 
Collect blood into a K2 EDTA plasma tube and mix by inversion 10 times. Centrifuge to separate plasma from cells within 1 hour of collection. Carefully transfer plasma into 2 separate polypropylene tubes or 2 separate Quest issued polypropylene pour-off/transfer tubes. Do not transfer to conical tubes. If unable to centrifuge within 1 hour of collection, store tube on ice. Store frozen.
Transport Temperature Frozen
Specimen Stability
Room temperatureUnacceptable
Refrigerated72 hours
Frozen28 days
Set-up/Analytic Time Set up: Mon-Sat; Report available: 3-5 days
Reference Range
Result CodeResult NameReference RangeUnit Of MeasureLOINC CodeComponent Name
86039422ABeta 42Not Establishedpg/mL33200-7Amyloid beta 42 peptide
86039423ABeta 40Not Establishedpg/mL70073-2Amyloid beta 40 peptide
86039424ABeta 42/40 Ratio> or = 0.170101806-8Beta-Amyloid
86039425AD Detect p-tau217, P< or = 0.15pg/mL104663-0Tau protein.phosphorylated 217
Methodology Liquid Chromatography/Tandem Mass Spectrometry, Immunoassay
Performing Site Quest Diagnostics Nichols Institute, San Juan Capistrano
Interface Mapping
Reporting Title: AD-Detect AB 42/40, 217,P
Result CodeResult NameLOINC CodeComponent Name
86039418InterpretationPending assignment
86039422ABeta 4233200-7Amyloid beta 42 peptide
86039423ABeta 4070073-2Amyloid beta 40 peptide
86039424ABeta 42/40 Ratio101806-8Beta-Amyloid
86039425AD Detect p-tau217, P104663-0Tau protein.phosphorylated 217
86039419AD Detect Likelihood ScorePending assignment
NPM1 Mutation for MRD, Quantitative PCR
Clinical Significance NPM1, encoding the nucleophosmin protein, is mutated in about 30% of the AML patients and the mutations are predominantly a 4-base insertion which causes a frameshift of the NPM1 protein at amino acid sequence 288 near the C-terminus. NPM1, Quantitative for MRD is an allele-specific qPCR assay designed to quantitatively detect the presence of the NPM1 mutation found previously as a way to assess the minimal/measurable residual disease (MRD) status after initial induction therapy for prognosis of disease progression and consideration of consolidation treatment selection.
Effective Date 3/3/2025
Test Code 13694
CPT Codes 81310
Specimen Requirements Preferred:
5 mL (3 mL minimum) whole blood or 3 mL (1mL minimum) bone marrow collected in an EDTA (lavender-top) tube
 
Acceptable:
Whole blood or bone marrow collected in a sodium heparin (green-top) tube
or

50 uL (20 uL minimum) of 10 ng/uL extracted RNA submitted in a microcentrifuge tube
Instructions Do not reject. Specimen viability decreases during transit. Send specimen to testing lab for viability determination.
 
Extracted RNA: In addition, only accept extracted DNA when extraction or isolation is performed in an appropriately qualified laboratory such as a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or CMS.
Transport Temperature Blood and Bone marrow: Room temperature
RNA: Frozen
Specimen Stability
Blood and Bone marrowRoom temperaturePreferred
Blood and Bone marrowRefrigeratedAcceptable
Blood and Bone marrowFrozenUnacceptable
RNARoom temperatureUnacceptable
RNARefrigeratedAcceptable
RNAFrozenPreferred
Set-up/Analytic Time Set up: Daily; Report available: 5-7 days
Reference Range
Result CodeResult NameReference RangeUnit Of MeasureLOINC CodeComponent Name
86038447NPM1 MutationNot Detected54448-6NPM1 gene targeted mutation analysis
86038448NPM1 Ratio%Pending assignment
Methodology Polymerase Chain Reaction
Performing Site Quest Diagnostics Nichols Institute, San Juan Capistrano
Interface Mapping
Reporting Title: NPM1 MUT for MRD,QN PCR
Result CodeTypeResult NameLOINC CodeComponent Name
86038447NPM1 Mutation54448-6NPM1 gene targeted mutation analysis
86038448NPM1 RatioPending assignment
86038449Prompt-Result (no return)Prior TherapyPending assignment
86038450Prompt-Result (no return)Sample Source31208-2Specimen source
Plasma Renin Activity with Reflex to Aldosterone
Clinical Significance The Aldosterone-renin ratio is used to screen for primary aldosteronism.
Effective Date 3/17/2025
Test Code 13817
CPT Codes 84244
Specimen Requirements 1.8 mL (0.8 mL minimum) frozen plasma collected in an EDTA (lavender-top) tube
Reject Criteria Moderate to gross hemolysis; plasma collected in a plasma separator tube; received thawed
Instructions Collect a mid-morning blood sample after patient has been upright (sitting, standing, or walking) for a minimum of 2 hours, then have them sit 5-15 minutes prior to collection
Transport Temperature Frozen
Specimen Stability
Room temperature and Refrigerated24 hours
Frozen28 days
Set-up/Analytic Time Set up: Sun-Fri; Report available: 4-6 days
Reference Range See Laboratory Report
Methodology Chromatography/Mass Spectrometry
Reflex: Liquid Chromatography/Tandem Mass Spectrometry
Performing Site Quest Diagnostics Nichols Institute, Chantilly
Interface Mapping
Result CodeResult NameLOINC CodeComponent Name
86038658PRA, LC/MS/MS2915-7Renin
This is a true reflex. Please build the unit code below separately. Non-orderable Reflex:
138191 - Aldosterone, LC/MS/MS
Result CodeResult NameLOINC CodeComponent Name
86038659Aldosterone, LC/MS/MS1763-2Aldosterone
Additional Information If Plasma Renin Activity result is <1.00 ng/mL/h, then Aldosterone will be performed at an additional charge (CPT code(s): 82088).